DNL952
Phase 1Small molecule
DNL952 is one of 8 small molecule programs targeting Pompe Disease. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Pompe Disease
#DrugCompanyPhaseTrials
1Rituxan
RocheApproved
Trexall
Jazz PharmaceuticalsApproved
Lumizyme
GGenzyme, a Sanofi Company
Approved
Velcade
SShilpa Grover, MD, MPH
Approved
Avalglucosidase Alfa
SanofiPhase 2
S-606001
ShionogiPhase 2
Neupogen
EEastern Cooperative Oncology Group
Preclinical
DNL952
DDenali Therapeutics Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DNL952. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- DDenali Therapeutics Inc.